Evidence map›Paper›PMID 42344889›Full record

ArticleFrontiers in immunology2026

Tetrandrine enhances anti-PD-1 immunotherapeutic efficacy for hepatocellular carcinoma by activating STING/TBK1/IRF3 pathway.

Biao Zheng, Guojun Yao, Yuli Pang, Jielong Luo, Zhiyong Yang, Fengmin Xiu, Chaohui Zhen, Rui Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Biao ZhengDepartment of Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Guojun YaoDepartment of Geriatrics, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
Yuli PangHealth Management Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Jielong LuoDepartment of Gastrointestinal Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Zhiyong YangDepartment of Gastrointestinal Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Fengmin XiuDepartment of Gastrointestinal Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Chaohui ZhenDepartment of Gastrointestinal Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Rui LiangDepartment of Gastrointestinal Surgery, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatocellular carcinoma (HCC) remains a significant global public health risk, and its mortality rate remains high. Tetrandrine (TET) inhibits tumor growth, but its combination with anti-PD-1 immunotherapy has not been fully elucidated. Methods: STING was knocked down in HCC cells, and CD8 Results: TET significantly inhibited HCC growth and induced apoptosis. It also promoted CD8 Discussion: By activating STING/TBK1/IRF3 signaling, TET enhanced CD8

Indexed as

BenzylisoquinolinesCarcinoma, HepatocellularInterferon Regulatory Factor-3Liver NeoplasmsMembrane ProteinsProtein Serine-Threonine KinasesAnimalsCD8-Positive T-LymphocytesCell Line, TumorcGAS-STING Signaling PathwayFemaleHumansImmunotherapyMaleMiceSignal TransductionBenzylisoquinolinesInterferon Regulatory Factor-3IRF3 protein, humanMembrane ProteinsProtein Serine-Threonine KinasesSTING1 protein, humanSTING ProteinTBK1 protein, humantetrandrineCD8+ T cellshepatocellular carcinomaPD-1STING/TBK1/IRF3 signaling pathwaytetrandrine

Identifiers

PMID42344889
PMCPMC13287138

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.